Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PPM1B | O75688 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414106 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL10891263 | 0.92 | HCAR2 (0.46) | HCAR2LMNASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL28088707 | 0.86 | HCAR2 (0.42) | HCAR2LMNASMN1; SMN2GAAALDH1A1 | |
| Hydrazine SCHEMBL1234309 | 0.86 | ALDH1A1 (0.54) | HCAR2LMNASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL138475 | 0.81 | HCAR2 (0.48) | HCAR2LMNASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL1948952 | 0.80 | ALDH1A1 (0.58) | HCAR2LMNASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL1401947 | 0.80 | ALDH1A1 (0.58) | HCAR2LMNASMN1; SMN2ALDH1A1TSHR | |
| Hydrazine SCHEMBL289463 | 0.79 | ALOX15 (0.50) | HCAR2LMNASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL8622644 | 0.79 | — | — | |
| Furan SCHEMBL28105844 | 0.79 | LMNA (0.43) | HCAR2LMNASMN1; SMN2GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108746656-B | Pre-alloyed powder for diamond products and preparation method thereof | 威海职业学院 | 2021-11-26 | — | — | CN | claimed |
| US-7943636-B2 | 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| CN-101084217-B | Imidazo [4,5-B] pyridin-2-ones and oxazolido [4,5-B] pyridin-2-ones and analogues thereof as therapeutic compounds | CANCER REC TECH LTD | 2010-10-13 | — | — | CN | disclosed |
| EP-2197875-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2010-06-23 | — | — | EP | disclosed |
| US-20090163533-A1 | 1-Substituted Pyrazolo (3,4-C) Ring Compounds as Modulators of Cytokine Biosynthesis for the Treatment of Viral Infections and Neoplastic Diseases | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| WO-2009037222-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090076275-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. | 2009-03-19 | — | — | US | disclosed |
| EP-1863814-A1 | 1-SUBSTITUTED PYRAZOLO (3,4-C) RING COMPOUNDS AS MODULATORS OF CYTOKINE BIOSYNTHESIS FOR THE TREATMENT OF VIRAL INFECTIONS AND NEOPLASTIC DISEASES | Coley Pharmaceutical Group, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| CN-101084217-A | Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds | CANCER REC TECH LTD (GB) | 2007-12-05 | — | — | CN | disclosed |
| CN-1330647-C | Heterobicyclic substituted phenyl * oxazolidinone antibacterial agents | ORTHO MCNELL PHARMACEUTICAL IN (US) | 2007-08-08 | — | — | CN | disclosed |
| CN-1414964-A | heterobicyclic substituted phenyl oxazolidinone antibacterial agents | ORTHO MCNELL PHARMACEUTICAL IN (US) | 2003-04-30 | — | — | CN | disclosed |
| US-6407114-B1 | BENIGN PROSTATIC HYPERPLASIA, CARDIOVASCULAR, GASTROINTESTINAL AND RESPIRATORY DISORDER TREATMENT; ANTIASTHMATIC, ANTIALLERGEN, AND ANTIDIABETIC AGENTS | PFIZER INC. | 2002-06-18 | — | — | US | disclosed |
| EP-1171122-A4 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-1171122-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| US-6248755-B1 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS; AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2001-06-19 | — | — | US | disclosed |
| WO-2000059502-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-0995751-A2 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. (US) | 2000-04-26 | — | — | EP | disclosed |
| US-4075222-A | VETERINARY MEDICINE, BACTERICIDES, FUNGICIDES, ANTIPROTOZOAN | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
| US-3980794-A | Method for promoting growth of poultry with 3-(5-nitro-2-imidazolyl)pyrazoles | ELI LILLY AND COMPANY (US) | 1976-09-14 | — | — | US | disclosed |
| US-3947467-A | ANTIBACTERIAL, ANTIPROTOZOAL, ANTIFUNGAL | ELI LILLY AND COMPANY (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076275-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT2, DGAT1, LCAT | HCAR2 2111/4885LMNA 4364/4885SMN1; SMN2 4066/4885 |
| US-20090163533-A1 | 1-Substituted Pyrazolo (3,4-C) Ring Compounds as Modulators of Cytokine Biosynthesis for the Treatment of Viral Infections and Neoplastic Diseases | IL2, IL4, IFNG | HCAR2 2145/4885LMNA 3081/4885SMN1; SMN2 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.